3 / 24
Page 45
Notes:
Journal of Pharmaceutical care and Health Systems | ISSN: 2376-0419 | Volume 5
Pharmaceutical sciences
11
th
World Congress on
September 28-29, 2018 | Montreal, Canada
Assessment of prescribing statins in patients with metabolic syndrome without established coronary
heart disease in khartoum
Ameera Mohammed Elhassan Osman Algezouli, Bashier Ibrahim Osman
and
Sulaf Ibrahim Abdelaziz
University of Khartoum, Sudan
M
etabolic syndrome (MetS) comprises a cluster of abnormalities. Four diagnostic criteria have been identified by the
National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III), and the presence of any three
features confirms the diagnosis. These include Central obesity, dyslipidemia, and impaired fasting Glucose. As metabolic
syndrome is driving the global epidemics of type 2 diabetes and cerebrovascular disease (CVD), there is an overwhelming
medical and economic effort to identify those individuals with metabolic syndrome early to make interventions to prevent
the development of diabetes and/or cardiovascular disease. Statins are lipid-lowering drugs that considered as cornerstones
of treatment in patients with MetS to reduce the risk for development of CVD. Objectives: To assess the appropriateness of
prescribing statin therapy in MetS patients in accordance with the NCEP-ATP III guidelines and the National Institute for
Health and Care Excellence (NICE).
Methodology:
The study was a cross-sectional descriptive study conducted at hospitals in Khartoum State, Sudan in the period
from January 2015 to March 2015. Eighty registrars were interviewed.
Results:
75% of registrars knew the diagnostic criteria for metabolic syndrome with only 3% of them performed CVD risk
assessment. And laboratory investigations before and after treatment; Lipid profile was performed by 82% of registrars under
study, followed by Creatine kinase (CK) level test (67%), liver function test (LFT, 56%), and follow up LFT was performed by
only 45% of the registrars investigated. The main drug prescribed by registrars was atorvastatin (97%). 59% of the registrars
investigated had poor knowledge about statins drug interactions and only 5% of them managed those interactions when they
have happened. On the other hand, adverse effects were found to be managed by only 4% of registrars understudy.
Conclusion:
Despite being acquainted with the Guidelines few registrars followed them. Reinforcement to follow them is
needed.
Ameera Mohammed Elhassan Osman Algezouli et al., J Pharma Care Health Sys 2018, Volume 5
DOI: 10.4172/2376-0419-C3-033